Loading…
Ocugen, Inc. is projected to rise to $1.51 by 2027, a +3% move from its current price of $1.47. OCGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.42 | $1.47 | $1.52 | -0.01% |
| Jul 14 | $1.40 | $1.47 | $1.54 | -0.01% |
| Jul 15 | $1.38 | $1.47 | $1.56 | -0.02% |
| Jul 16 | $1.37 | $1.47 | $1.58 | -0.03% |
| Jul 17 | $1.36 | $1.47 | $1.59 | -0.04% |
| Jul 18 | $1.35 | $1.47 | $1.60 | -0.04% |
| Jul 19 | $1.34 | $1.47 | $1.61 | -0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.34 | $1.47 | $1.61 | -0.05% |
| Week 2 | $1.29 | $1.47 | $1.67 | -0.10% |
| Week 3 | $1.25 | $1.47 | $1.72 | -0.15% |
| Week 4 | $1.22 | $1.47 | $1.77 | -0.20% |
| Week 5 | $1.19 | $1.47 | $1.81 | -0.25% |
| Week 6 | $1.17 | $1.47 | $1.84 | -0.30% |
| Week 7 | $1.15 | $1.46 | $1.87 | -0.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. Its pipeline includes OCU400, a novel gene therapy candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for retinitis pigmentosa and Phase 1/2 trials for Leber congenital amaurosis.
OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration; and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult.
In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates.
The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Ocugen, Inc. (OCGN) is a Healthcare stock with a current price of $1.53 and a market cap of $517.94M, ranking 3018 by market size. The stock shows a bullish tilt in sentiment, with near-term technicals aligning with a constructive path ahead.
The current price sits amid notable moving averages, with the 50-day simple moving average at $1.44 and the 200-day simple moving average at $1.55. These levels frame a near-term balance between support and resistance that traders watch closely.
A major floor 35.4% below — a decisive break under it would weaken the trend.
The nearest floor, 19.7% below — buyers have tended to step in here.
The nearest ceiling, 13.6% above — a clean break opens room to run.
A major ceiling 68.7% above — clearing it would confirm fresh momentum.
Key OCGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OCGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.49 | Sell | $1.48 | Sell |
| MA 10 | $1.51 | Sell | $1.47 | Sell |
| MA 20 | $1.39 | Buy | $1.43 | Buy |
| MA 50 | $1.41 | Buy | $1.46 | Buy |
| MA 100 | $1.64 | Sell | $1.51 | Sell |
| MA 200 | $1.55 | Sell | $1.47 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.77 | Neutral |
| Stoch RSI (14) | 32.14 | Neutral |
| CCI (20) | 43.24 | Neutral |
| Williams %R (14) | -52.63 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 6.52 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 47.37 | Neutral |
| TRIX (15) | 0.24 | Buy |
| Awesome (5,34) | 0.12 | Buy |
| Ultimate (7,14,28) | 42.66 | Neutral |
| Momentum (10) | 0.10 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 1.47 | Sell |
| ADX (14) | 18.14 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is broadly neutral to bullish, with RSI(14) at 60 signaling balanced momentum. The price hovers around the SMA50 of $1.44 and the SMA200 of $1.55, placing it between these key averages.
A defined trading range persists, with a 30-day range of $1.16 to $2.02. Support sits at $1.18 and resistance at $1.67, indicating potential for upside movement but with defined caps in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.18 | $1.47 | $1.91 | 0% | Neutral | |
| $1.17 | $1.51 | $2.08 | +3% | Neutral | |
| $1.26 | $1.69 | $2.43 | +15% | Neutral | |
| $1.46 | $2.02 | $3.02 | +38% | Bullish | |
| $1.58 | $2.24 | $3.45 | +53% | Bullish | |
| $1.62 | $2.36 | $3.72 | +60% | Bullish | |
| $1.50 | $2.23 | $3.60 | +52% | Bullish | |
| $1.49 | $2.27 | $3.74 | +54% | Bullish | |
| $1.59 | $2.47 | $4.15 | +68% | Bullish | |
| $1.88 | $3.00 | $5.13 | +104% | Bullish | |
| $1.95 | $3.41 | $6.28 | +132% | Bullish | |
| $3.58 | $7.42 | $15.18 | +405% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.18 | $1.47 | $1.72 | +0.00% |
| August 2026 | $1.19 | $1.41 | $1.73 | -4.10% |
| September 2026 | $1.22 | $1.46 | $1.82 | +3.60% |
| October 2026 | $1.21 | $1.46 | $1.84 | -0.01% |
| November 2026 | $1.18 | $1.43 | $1.82 | -1.98% |
| December 2026 | $1.22 | $1.49 | $1.91 | +4.12% |
Click any year to see its month-by-month OCGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, OCGN is projected to trade between $1.18 and $1.91, averaging $1.47 — a potential gain of 0% from today's $1.47. Price action looks broadly range-bound.
Ocugen, Inc.'s 2027 outlook centres on $1.51, within a $1.17 to $2.08 range. That is up +3% on the projected 2026 average. That marks a +3% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, OCGN could reach as high as $2.43, with a base case around $1.69 and support toward $1.26 — roughly +15% from $1.47. Price action looks broadly range-bound.
Expect OCGN to range from $1.46 to $3.02 through 2029. The $2.02 average target implies a +38% move from current prices. That is up +20% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The OCGN price prediction for 2030 points to an average of $2.24 (low $1.58, high $3.45) — a potential gain of +53% on today's $1.47. Momentum favours further upside here.
In 2031, OCGN is projected to trade between $1.62 and $3.72, averaging $2.36 — a potential gain of +60% from today's $1.47. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Ocugen, Inc.'s 2032 outlook centres on $2.23, within a $1.50 to $3.60 range. That is -5% versus the projected 2031 average. That marks a +52% change versus current levels. Momentum favours further upside here.
By 2033, OCGN could reach as high as $3.74, with a base case around $2.27 and support toward $1.49 — roughly +54% from $1.47. Buyers look set to stay in control over this stretch.
Expect OCGN to range from $1.59 to $4.15 through 2034. The $2.47 average target implies a +68% move from current prices. That is up +9% on the projected 2033 average. Momentum favours further upside here.
The OCGN price prediction for 2035 points to an average of $3.00 (low $1.88, high $5.13) — a potential gain of +104% on today's $1.47. Buyers look set to stay in control over this stretch.
In 2040, OCGN is projected to trade between $1.95 and $6.28, averaging $3.41 — a potential gain of +132% from today's $1.47. That is up +14% on the projected 2035 average. Momentum favours further upside here.
Ocugen, Inc.'s 2050 outlook centres on $7.42, within a $3.58 to $15.18 range. That is up +117% on the projected 2040 average. That marks a +405% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in OCGN today (≈ 680.272109 OCGN) could be worth
$5,046.79
+$4,046.79 (+405%) by 2050 · US Dollar
Based on the average projected OCGN price of $7.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OCGNwould be worth at today's price.
$1,000 invested in OCGN on Jul 10, 2025 (≈ 869.565235 OCGN) would be worth
$1,278.26
+$278.26 (+27.8%) today · 1.28× · US Dollar
Based on a OCGN entry price of $1.15 vs. today's $1.47.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.51 | $973.51 | -2.6% |
| 1 month ago | $1.19 | $1,235.29 | +23.5% |
| 3 months ago | $1.76 | $835.23 | -16.5% |
| 6 months ago | $1.78 | $825.84 | -17.4% |
| 1 year ago | $1.15 | $1,278.26 | +27.8% |
| All time (5.0y) ago | $6.72 | $218.75 | -78.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OCGN forecast.
Our base-case forecast reaches $2.90 around 2035.
Implied market cap at $2.90: $981.71M
The year-by-year forecast shows a generally bullish trajectory after 2026, with the avg price rising in the years that follow and substantial ROIs.
In 2026, the avg price is projected at $1.53 with a neutral sentiment and 0% ROI, followed by continued upside in subsequent years: 2027 avg $1.65 (ROI 7.8%), 2028 avg $2.02 (ROI 31.7%), 2029 avg $2.58 (ROI 68.9%), and 2030 avg $2.79 (ROI 82.6%). The forecast remains bullish through 2031–2035, with 2031 avg $2.99 (ROI 95.5%), 2032 avg $2.87 (ROI 87.7%), 2033 avg $2.88 (ROI 88.5%), 2034 avg $3.46 (ROI 125.9%), and 2035 avg $4.40 (ROI 187.5%).
Further out, 2040 is forecast at avg $5.01 (ROI 227.3%), and 2050 at avg $11.68 (ROI 663.5%), with sentiment staying bullish. These figures illustrate a long-run upside path, though they are estimates and carry inherent uncertainty.
Tap a question to reveal the answer.
In 2030, the avg forecast price is $2.79 with an expected ROI of 82.6%. The year’s min is $1.87 and the max is $4.52.
The 2026 forecast is neutral with an avg of $1.53 and 0% ROI. Longer-term years show bullish potential (e.g., 2027 avg $1.65; 2028 $2.02; 2029 $2.58; 2030 $2.79), but these are estimates and not guarantees.
Yes. The forecast includes a max of $5.05 in 2033, $6.19 in 2034, $8.03 in 2035, $9.93 in 2040, and $26.04 in 2050.
The 2040 avg price is forecast at $5.01 with a projected ROI of 227.3%.
The current price is $1.53 and the annualized volatility is 80%.
Ocugen, Inc. Community Discussion
0Share your Ocugen, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.